ME-ACP: Multi-view neural networks with ensemble model for identification of anticancer peptides

Comput Biol Med. 2022 Jun:145:105459. doi: 10.1016/j.compbiomed.2022.105459. Epub 2022 Mar 26.

Abstract

Cancer remains one of the most threatening diseases, which kills millions of lives every year. As a promising perspective for cancer treatments, anticancer peptides (ACPs) overcome a lot of disadvantages of traditional treatments. However, it is time-consuming and expensive to identify ACPs through conventional experiments. Hence, it is urgent and necessary to develop highly effective approaches to accurately identify ACPs in large amounts of protein sequences. In this work, we proposed a novel and effective method named ME-ACP which employed multi-view neural networks with ensemble model to identify ACPs. Firstly, we employed residue level and peptide level features preliminarily with ensemble models based on lightGBMs. Then, the outputs of lightGBM classifiers were fed into a hybrid deep neural network (HDNN) to identify ACPs. The experiments on independent test datasets demonstrated that ME-ACP achieved competitive performance on common evaluation metrics.

Keywords: Anticancer peptides; Convolutional neural network; Long short term memory; Peptide level feature; Residue level feature.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Antineoplastic Agents* / therapeutic use
  • Humans
  • Neoplasms* / drug therapy
  • Neural Networks, Computer
  • Peptides / chemistry

Substances

  • Antineoplastic Agents
  • Peptides